LOS ANGELES—A U.S. district court in San Diego Aug. 20 dismissed most claims brought against executives of Intelligent Bio-Systems Inc. (IBS) by Azco Biotech Inc. after an agreement between the companies involving DNA sequencing technology ended when Netherlands holding company Qiagen NV acquired IBS (Azco Biotech, Inc. v. Qiagen N.V., S.D. Cal., 3:12-cv-02599-BEN-DHB, 8/20/13).
The U.S. District Court for the Southern District of California also dismissed Qiagen from the case for lack of personal jurisdiction, and dismissed claims against both IBS and its executives as individual defendants for intentional and negligent interference with prospective economic advantage.
However, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.